

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2020/176699 A1

(43) International Publication Date
03 September 2020 (03.09.2020)

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 39/395 (2006.01)
A61K 39/00 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2020/020018

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

27 February 2020 (27.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/811,827 28 February 2019 (28.02.2019) US

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors: **FURY, Matthew G.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **LOWY, Israel**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(74) Agent: **EL HIOUM, Dianna G.** et al.; Fox Rothschild LLP, 997 Lenox Drive, Lawrenceville, NJ 08648-2311 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ADMINISTRATION OF PD-1 INHIBITORS FOR TREATING SKIN CANCER

(57) Abstract: The disclosure relates to methods for treating or inhibiting the growth of a tumor in a patient with a skin cancer, wherein the methods include administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an antibody or antigen-binding fragment thereof that specifically binds PD-1, PD-L1, and/or PD-L2). In certain embodiments, the method includes administering to the patient a therapeutically effective amount of a PD-1 inhibitor as adjuvant treatment after the patient has completed surgery and optionally radiation therapy for skin cancer, such as CSCC, and is at high risk for disease recurrence. In certain embodiments, the method includes administering to the skin cancer patient a therapeutically effective amount of a PD-1 inhibitor as neoadjuvant treatment before planned surgery for skin cancer. In certain embodiments, the method includes administering to skin cancer patient a therapeutically effective amount of a PD-1 inhibitor as neoadjuvant treatment before planned surgery for skin cancer and subsequently administering to the patient a PD-1 inhibitor as adjuvant therapy after such surgery.



WO 2020/176699 A1